Bridgeway Capital Management, LLC Medicinova Inc Transaction History

Bridgeway Capital Management, LLC

$4.44 Billion
Q3 2024

A detailed history of Bridgeway Capital Management, LLC transactions in Medicinova Inc stock. As of the latest transaction made, Bridgeway Capital Management, LLC holds 145,147 shares of MNOV stock, worth $265,619. This represents 0.01% of its overall portfolio holdings.

Number of Shares

145,147

Previous 145,147 -0.0%

Holding current value

$265,619

Previous $209,000 45.45%

% of portfolio

0.01%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$1.95 - $2.54 $97,500 - $127,000	-50,000 Reduced 25.62%	145,147 $313,000
Q2 2022 Aug 15, 2022	SELL	$2.31 - $3.14 $23,100 - $31,400	-10,000 Reduced 4.87%	195,147 $494,000
Q1 2022 May 16, 2022	SELL	$2.19 - $2.81 $32,850 - $42,150	-15,000 Reduced 6.81%	205,147 $548,000
Q4 2021 Feb 14, 2022	BUY	$2.61 - $4.42 $104,139 - $176,358	39,900 Added 22.14%	220,147 $590,000
Q3 2021 Nov 15, 2021	BUY	$3.4 - $4.24 $265,200 - $330,720	78,000 Added 76.29%	180,247 $683,000
Q2 2021 Aug 16, 2021	BUY	$3.76 - $5.14 $125,527 - $171,598	33,385 Added 48.48%	102,247 $435,000
Q1 2021 May 17, 2021	BUY	$4.81 - $8.74 $331,226 - $601,853	68,862 New	68,862 $348,000
Q2 2019 Aug 14, 2019	SELL	$8.29 - $13.22 $1.06 Million - $1.69 Million	-127,710 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$7.65 - $12.83 $38,250 - $64,150	-5,000 Reduced 3.77%	127,710 $1.04 Million
Q3 2018 Nov 13, 2018	BUY	$7.06 - $12.49 $247,100 - $437,150	35,000 Added 35.82%	132,710 $1.66 Million
Q2 2018 Aug 14, 2018	SELL	$7.96 - $13.23 $329,321 - $547,351	-41,372 Reduced 29.75%	97,710 $778,000
Q3 2017 Nov 14, 2017	BUY	$4.43 - $6.58 $616,133 - $915,159	139,082	139,082 $886,000

Others Institutions Holding MNOV

# of Institutions

Shares Held

4.83M

Call Options Held

9.4K

Put Options Held

View Full List

About MEDICINOVA INC

Ticker MNOV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,046,200
Market Cap $89.8M
Description
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and ...

More about MNOV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bridgeway Capital Management, LLC with notifications on news.

Account

Bridgeway Capital Management, LLC Medicinova Inc Transaction History